XML 43 R28.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2022

Revenue by payor class as a percentage of total net service revenue is as follows:


	As of December 31,
	2022		2021		2020
Home Health:
Medicare	40	%	41	%	41	%
Non-Medicare - Episodic-based	8	%	8	%	7	%
Non-Medicare - Non-episodic based	13	%	12	%	13	%
Hospice:
Medicare	33	%	34	%	34	%
Non-Medicare	2	%	2	%	2	%
Personal Care	3	%	3	%	3	%
High Acuity Care (1)	1	%	—	%	—	%
	100	%	100	%	100	%

(1) Acquired Contessa Health on August 1, 2021.

Schedule of Cash Cash Equivalents and Restricted Cash

The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):


	As of December 31,
	2022		2021
Cash and cash equivalents	$	40.5	$	42.7
Restricted cash	13.6		3.1
Cash, cash equivalents and restricted cash	$	54.1	$	45.8

Schedule of Estimated Useful Lives of Property and Equipment

We generally provide for depreciation over the following estimated useful service lives.


			Years
Buildings			39
Leasehold improvements			Lesser of lease term or expected useful life
Equipment and furniture			3 to 7
Vehicles			3 to 5
Computer software			2 to 7
Finance leases			3

Schedule of Property and Equipment

The following table summarizes the balances related to our property and equipment for 2022 and 2021 (amounts in millions):


	As of December 31,
	2022		2021
Buildings and leasehold improvements	$	9.7	$	9.1
Equipment and furniture	56.9		54.7
Finance leases	4.1		4.5
Computer software	46.7		47.0
	117.4		115.3
Less: Accumulated depreciation	(101.4)		(96.9)
	$	16.0	$	18.4

Schedule of Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):


			Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of December 31, 2022		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-term obligations	$	436.1	$	—	$	428.6	$	—

Schedule of Weighted-Average Shares Outstanding

The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):


	For the Years Ended December 31,
	2022	2021	2020
Weighted average number of shares outstanding – basic	32,517	32,642	32,559
Effect of dilutive securities:
Stock options	39	122	420
Non-vested stock and stock units	97	208	289
Weighted average number of shares outstanding – diluted	32,653	32,972	33,268
Anti-dilutive securities	303	114	25